SB 3030 is the Mississippi State Board of Pharmacy’s fiscal year 2026 appropriation bill. It provides $3,958,339 in special funds to support the board’s operations from July 1, 2025 through June 30, 2026, and authorizes 20 permanent positions and no time-limited positions. The bill is a standard agency budget measure that funds licensure, compliance, disciplinary, and prescription monitoring functions, while also setting expectations for how the agency will manage personnel costs and report on performance.
The bill directs the board to operate within the appropriated amount, maintain detailed accounting and personnel records, and comply with state budgeting and personnel rules. It also includes specific authority for the board to escalate up to $500,000 of its budget under the Pharmacy Benefit Prompt Pay Act for compliance examinations and regulatory oversight, and to accept and spend funds from other state agencies for the Prescription Monitoring Program. The act is temporary and applies only to fiscal year 2026, with the appropriation expiring at the end of that fiscal year.
The bill’s impact on state law is primarily fiscal and administrative rather than substantive regulatory change. It does not create new pharmacy licensing rules or enforcement powers, but it reinforces existing statutory duties under the Mississippi Performance Budget and Strategic Planning Act, the Pharmacy Benefit Prompt Pay Act, and the Prescription Monitoring Program statute. It also sets performance targets for licensure turnaround, complaint resolution, investigations, and PMP registration, which the agency must report in its next budget request.
The overall sentiment around the bill appears strongly favorable and noncontroversial. It passed the Senate 50-0 and the House 120-0, indicating broad bipartisan support for funding the Board of Pharmacy and its regulatory work. The absence of committee transcript discussion suggests there was little public dispute or debate recorded around the measure.
The main points of contention, to the extent any are implied by the bill text, involve budget discipline and oversight rather than policy disagreement. The bill places limits on salary growth, vacancy funding, and position escalations, and requires approval from the Department of Finance and Administration before certain staffing changes can occur. It also emphasizes that general funds may not be used to replace withdrawn special or federal funds, reflecting legislative concern about fiscal controls, personnel management, and accountability.
SB 3030 appropriates special funds to the Mississippi State Board of Pharmacy for FY 2026 and authorizes 20 permanent positions, while imposing detailed conditions on how the agency may spend those funds. It reinforces existing state budgeting, personnel, and reporting requirements, including limits on salary actions, restrictions on position escalations, and mandatory performance reporting. The bill also authorizes up to $500,000 in budget escalation for Pharmacy Benefit Prompt Pay Act enforcement and allows the board to accept interagency funds for the Prescription Monitoring Program.
The bill appears to have been received positively and without controversy. It passed the Senate unanimously and later passed the House unanimously as amended, suggesting broad agreement that the Board of Pharmacy should be funded at the proposed level and that its regulatory and monitoring functions should continue without interruption. No committee transcript was provided, and the voting history indicates little to no opposition.
There is no clear substantive policy dispute in the available record, but the bill does contain the kinds of fiscal controls that can sometimes draw scrutiny: limits on personnel spending, restrictions on using vacancy funds for salary increases, and requirements for approval before escalating positions or funds. The legislature also emphasizes that the agency must not exceed its appropriation and must maintain detailed records, which reflects concern about accountability and budget discipline rather than disagreement over pharmacy policy. The unanimous votes suggest these issues were not contentious in practice.